Skip to main content

Table 2 Results of stereotactic radiosurgery (SRS) for brain metastases

From: Stereotactic radiosurgery (SRS) for brain metastases: a systematic review

Reference

n(patients/lesions)

Prescribed dose (median; range [Gy])*

Median OS (m)

1-year PFS (%)

Pirzkall et al. 1998 [28]

236/311

20; 10-30

5.5

89

Cho et al. 1998 [81]

73/136

17.5; 6-50

7.8

80

Sneed et al. 1999 [27]

62/118a

18; 15-22

11.3

80

43/117b

17.5; 15-22

11.1

86

Varlotto et al. 2003 [82]

137/208

16; 12-25

Not given

90

Andrews et al. 2004 [18]

164/269c

Not given; 15-24

6.5

82

Bhatnagar et al. 2006 [83]

205/4-18 lesions eachd

16; 12-20

8.0

71

  1. OS: overall survival in months; PFS: progression-free survival.
  2. *Prescription isodose or point varied, some series included SRS plus WBRT.
  3. aSRS only.
  4. bSRS plus WBRT (no significant difference in OS and PFS between both groups).
  5. cSRS plus WBRT.
  6. dSRS plus/minus WBRT.